profit from every $100 of sales.
$0$100
Galapagos
We have no price for Galapagos since 2 July 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$30.39+2.67% today
-10.4% since Oct 13, 25
1-year low $26.611-year high $34.64
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $5.83 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Galapagos sold, what it kept, and what it did with the cash.
Sales went from $241 million in 2022 to $1.11 billion in 2025, with $321 million of profit last year.
SalesProfit
Galapagos vs. similar companies
Galapagos grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Galapagos | 5.8× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Galapagos's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 241 | 240 | 276 | 1,112 | |
| 241 | 240 | 241 | 1,083 | |
| -131 | -88 | -188 | 501 | |
| 4 | 51 | 43 | 359 | |
| -218 | 212 | 74 | 321 | |
| -3.32 | 3.21 | 1.12 | 4.87 | |
| 100.0% | 100.0% | 87.4% | 97.3% | |
| -54.3% | -36.8% | -68.3% | 45.1% | |
| -90.4% | 88.3% | 26.9% | 28.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 4,734 | 4,357 | 4,136 | 3,407 |
| Cash | 508 | 167 | 64 | 88 |
| Total debt | 22 | 10 | 12 | 7 |
| Total liabilities | 2,208 | 1,562 | 1,239 | 171 |
| 2,526 | 2,796 | 2,897 | 3,236 | |
| 66 | 66 | 66 | 66 | |
| -1.9% | 0.2% | -0.1% | 7.4% | |
| -8.6% | 7.6% | 2.6% | 9.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -501 | -406 | -320 | -257 | |
| 37 | 19 | 82 | 14 | |
| -537 | -425 | -402 | -271 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 89 | 57 | 20 | 24 |
Valuation
- 5.8×
- –
- –
- –
- 1.7×
- –
- 5.0×
- -14.5%
- 17.2%
- –
Profitability
- 97.3%
- 45.1%
- 28.9%
- –
- –
- –
- –
- –
- –
- –
Growth
- +66.4%
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 4%of 898
Top 3%of 651
Top 8%of 911
Bottom 6%of 991
What analysts expect
- Average price target
- $33.00
- Range
- $33.00 – $33.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.25 | -1.27 | +119.7% |
| Feb 23, 2026 | 16.38 | 1.00 | +1,538.0% |
| Nov 5, 2025 | -3.59 | -0.20 | −1,696.4% |
| Jul 23, 2025 | -1.89 | -0.67 | −182.3% |
| Apr 23, 2025 | -2.47 | -0.23 | −973.9% |
| Feb 28, 2025 | 0.39 | -0.24 | +263.3% |
| Oct 30, 2024 | -0.77 | -0.27 | −185.2% |
| Sep 12, 2024 | 0.14 | 0.03 | +450.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
32No pass
Benjamin Graham
28No pass
Philip Fisher
56No pass
Peter Lynch
76Pass
Joel Greenblatt
40No pass
Charlie Munger
46No pass
Terry Smith
47No pass
Questions about Galapagos
Is Galapagos a good stock to buy?
A strong, very profitable business, and the price looks low. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Galapagos AI analysis
What does Galapagos do?
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. It is in Biotechnology.
Does Galapagos pay a dividend?
No. Galapagos does not pay a dividend at the moment.
Who are Galapagos's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Galapagos's.
Prices: daily closes to Jul 2, 2026. Fundamentals: company reports via invest-like data.